Questions on variant Creutzfeldt–Jakob disease and blood transfusion
Risk assessment
Two developments in the field of variant Creutzfeldt–Jakob disease (vCJD) occurred in 2009. In order to address a number of questions that were raised, ECDC internal and external experts prepared this risk assessment. The document focuses on how these new facts affect the current assumptions regarding transmissibility of the disease through blood transfusion and tissue/cells transplantation.
Publication file
110921_TER_Risk assessment_vCJD.pdf
English (598.7 KB - PDF)Related content
Share this page